(Nanoscope Technologies) Nanoscope Technologies LLC, a biotechnology company developing gene therapies for treatment of retinal diseases, is featuring multiple scientific presentations highlighting its groundbreaking research on optical gene delivery for vision restoration and OCT-guided electrophysiology platforms for characterization of retinal degeneration and assessment of efficacy of cell-gene therapy at the 2021 ARVO annual (virtual) meeting, May 1-7. Nanoscope's Multi-Characteristics Opsin (MCO) when delivered into cells to reprograms cells to sense ambient light, thus allowing vision restoration in patients with retinal degeneration.
The text above is a summary, you can read full article here.